NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting
October 19 2023 - 8:00AM
NexImmune, Inc. a biotechnology company developing a novel approach
to immunotherapy designed to orchestrate a targeted immune response
by directing the function of antigen-specific T cells in oncology,
autoimmune and infectious diseases, today announced that three
abstracts have been accepted for poster presentation at the
upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual
Meeting in San Diego, CA , being held November 1-5, 2023.
“We are pleased that abstracts highlighting recent advances in
our AIM injectable program demonstrating the ability to generate
broad polyclonal T cell responses from memory and naive
populations, as well as the synergistic benefit of a novel IO AIM
ACT combination in the oncology setting, have been selected for
presentation at SITC 2023,” said Kristi Jones, Chief Executive
Officer of NexImmune. “These abstracts showcase the continued
advancement of our platform and its therapeutic potential in
cancer, autoimmune and infectious diseases.”
Poster Presentation Details:
Title: Efficacy of injectable antigen
presenting nanoparticles (AIM INJ), in solid tumor
modelsAbstract Number:
1139Category: Poster
PresentationAuthors: Haiyun Liu, Duong Nguyen,
Durgadas Cherukaraveedu, Adam Parks, Bryan Hahn, Daniel Dembrow,
Sojung Kim, Jack Ragheb, Aniket Wadajkar, Mathias OelkeDate
& Time: Friday, Nov. 3, 2023 9 a.m. – 7 p.m.
Exhibit Hall A
Title: Enhancement of bispecific T Cell
engagers (bispecific TCE) killing potency in AML with NexImmune
Artificial Immune Modulation (AIM) Adoptive Cell Therapy (ACT) T
cellsAbstract #: 395Category:
Poster PresentationAuthors: Ruipeng Wang, Mathias
Oelke, Shweta Jain, Sojung Kim, Jack Ragheb, Adam Parks, Rui Wang,
Charles Reed, Brian Alvarez, Jerome Zeldis, Daniel
BednarikDate & Time: Friday, Nov. 3, 2023
9 a.m. – 7 p.m. Exhibit Hall A
Title: Artificial Immune Modulation (AIM)
nanoparticles expand antigen specific CD8 T cells from both naïve
and memory T cell populationsAbstract #:
396Category: Poster
PresentationAuthors: Ruipeng Wang, Lauren Suarez,
Bryan Hahn, Alison Farrell, Sojung Kim and Mathias
OelkeDate & Time: Saturday, Nov. 4, 2023
9 a.m. – 8:30 p.m. Exhibit Hall A
All posters presented at the poster hall will be made available
as virtual ePosters throughout the SITC 38th Annual Meeting.
About NexImmune
NexImmune is developing novel approach to
immunotherapy designed to employ the body’s own T cells to generate
a specific, potent, and durable immune response. The backbone of
NexImmune’s approach is a proprietary Artificial Immune Modulation
(AIM™) nanoparticle technology platform. The AIM technology enables
NexImmune to construct nanoparticles that function as synthetic
dendritic cells capable of directing a specific T cell-mediated
immune response. AIM constructed nanoparticles employ natural
biology to engage, activate and expand endogenous T cells in ways
that combine anti-tumor attributes of antigen-specific precision,
potency and long-term persistence with reduced potential for
off-target toxicities. NexImmune is focused on developing
injectable AIM nanoparticle constructs and modalities for potential
clinical evaluation in oncology, autoimmune disorders and
infectious diseases.
For more information, visit www.neximmune.com.
Forward Looking Statements
This press release may contain “forward-looking” statements
within the meaning of the Private Securities Litigation Reform Act
of 1995 that are based on the beliefs and assumptions and on
information currently available to management of NexImmune, Inc.
(the “Company”). All statements other than statements of historical
fact contained in this press release are forward-looking
statements, including statements concerning the impact of our
workforce reduction; the enrollment, timing, progress, release of
data from and results of the Company’s paused clinical trials and
the expectations with respect to potential AIM INJ product
candidates; the timing, progress and release of preclinical data
from our AIM INJ platform programs and other preclinical research
programs; the expectation of submitting an IND for NEXI-101
(injectable) in 2024; and the utility of prior preclinical and
clinical data in determining future clinical results. In some
cases, you can identify forward-looking statements by terminology
such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,”
“believes,” “estimates,” “predicts,” “potential” or “continue” or
the negative of these terms or other comparable terminology.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the Company’s actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. These risks and
uncertainties include, but are not limited to, the risks and
uncertainties set forth in the “Risk Factors” section of our Annual
Report on Form 10-K for the year ended December 31, 2022 filed
with the Securities and Exchange Commission (“SEC”) on
March 28, 2023, and subsequent reports that we file with the
SEC. Forward-looking statements represent the Company’s beliefs and
assumptions only as of the date of this press release. Although the
Company believes that the expectations reflected in the
forward-looking statements are reasonable, it cannot guarantee
future results, levels of activity, performance or achievements.
Except as required by law, the Company assumes no obligation to
publicly update any forward-looking statements for any reason after
the date of this press release to conform any of the
forward-looking statements to actual results or to changes in its
expectations.
CONTACT:Chad Rubincrubin@neximmune.com
NexImmune (NASDAQ:NEXI)
Historical Stock Chart
From Apr 2024 to May 2024
NexImmune (NASDAQ:NEXI)
Historical Stock Chart
From May 2023 to May 2024